Literature DB >> 7687701

Serum ELAM-1 is increased in vasculitis, scleroderma, and systemic lupus erythematosus.

C W Carson1, L D Beall, G G Hunder, C M Johnson, W Newman.   

Abstract

OBJECTIVE: To investigate the state of endothelial cell activation in vasculitis, scleroderma, and systemic lupus erythematosus (SLE).
METHODS: We used a sandwich ELISA to quantitate a soluble form of endothelial leukocyte adhesion molecule-1 (sELAM) in serum.
RESULTS: sELAM was detected in serum from healthy individuals (mean 0.92 ng/ml). Levels were significantly higher in patients with giant cell arteritis (mean 2.04 ng/ml), polyarteritis nodosa (mean 2.08 ng/ml), scleroderma (mean 2.27 ng/ml), and SLE (mean 3.93 ng/ml). Elevated values were present in patients with both active and inactive disease. sELAM levels of > 3 ng/ml identified most patients with recent onset or active disease.
CONCLUSION: Our findings may reflect a low degree of endothelial cell activation in healthy persons that is increased in inflammatory diseases involving blood vessels. Elevated serum sELAM levels may reflect ongoing inflammatory processes in these diseases.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7687701

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  17 in total

1.  Elevated serum L-selectin levels and decreased L-selectin expression on CD8(+) lymphocytes in systemic sclerosis.

Authors:  Y Shimada; M Hasegawa; K Takehara; S Sato
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

2.  Increased level of soluble E-selectin in the serum from patients with idiopathic pulmonary fibrosis.

Authors:  Seiji Hayashi; Kin'ya Abe; Hiroto Matsuoka; Sho Goya; Hiroshi Morishita; Masahide Mori; Toru Arai; Hiroshi Kida; Kazumi Nishino; Yoshito Takeda; Tadashi Osaki; Isao Tachibana; Kentaro Kimura; Soichiro Yokota; Yoshikazu Inoue; Mitsunori Sakatani
Journal:  Inflammation       Date:  2004-02       Impact factor: 4.092

Review 3.  Candidate-based proteomics in the search for biomarkers of cardiovascular disease.

Authors:  Leigh Anderson
Journal:  J Physiol       Date:  2004-12-20       Impact factor: 5.182

Review 4.  Clinical use of the measurement of soluble cell adhesion molecules in patients with autoimmune rheumatic diseases.

Authors:  P P Sfikakis; G C Tsokos
Journal:  Clin Diagn Lab Immunol       Date:  1997-05

5.  Circulating adhesion molecules ICAM-1, E-selectin, and von Willebrand factor in Henoch-Schönlein purpura.

Authors:  O Söylemezoglu; N Sultan; T Gursel; N Buyan; E Hasanoglu
Journal:  Arch Dis Child       Date:  1996-12       Impact factor: 3.791

6.  Increased serum levels of soluble L-selectin (CD62L) in patients with active systemic lupus erythematosus (SLE).

Authors:  J Font; P Pizcueta; M Ramos-Casals; R Cervera; M García-Carrasco; M Navarro; M Ingelmo; P Engel
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

7.  Serum thrombomodulin-a reliable marker of disease activity in systemic lupus erythematosus (SLE): advantage over established serological parameters to indicate disease activity.

Authors:  M W Boehme; U Raeth; P R Galle; W Stremmel; W A Scherbaum
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

8.  Levels of the circulating cell adhesion molecule E-selectin and disease progression in HIV infection.

Authors:  P P Sfikakis; V Tzavara; N Sipsas; O Kosmopoulou; P Sfikakis; T Kordossis
Journal:  Infection       Date:  1995 Jul-Aug       Impact factor: 3.553

9.  IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines.

Authors:  D Carvalho; C O Savage; C M Black; J D Pearson
Journal:  J Clin Invest       Date:  1996-01-01       Impact factor: 14.808

Review 10.  Vascular disease in scleroderma.

Authors:  Fredrick M Wigley
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.